Anti-CIP2A Polyclonal Antibody
- 發(fā)布日期： 2019-05-13
- 更新日期： 2025-07-11
產(chǎn)品詳請(qǐng)
| 產(chǎn)地 |
北京
|
| 品牌 |
Solarbio
|
| 保存條件 |
Store at -20°C. Avoid freeze / thaw cycles.
|
| 貨號(hào) |
K106617P
|
| 應(yīng)用范圍 |
WB
|
| CAS編號(hào) |
|
| 抗體名 |
Anti-CIP2A Polyclonal Antibody
|
| 克隆性 |
Polyclonal Antibody
|
| 靶點(diǎn) |
|
| 適應(yīng)物種 |
Human
|
| 形態(tài) |
|
| 宿主 |
Rabbit
|
| 亞型 |
IgG
|
| 標(biāo)識(shí)物 |
CIP2A;KIAA1524;Protein CIP2A;p90
|
| 濃度 |
%
|
| 免疫原 |
Recombinant protein of human CIP2A
|
Cancerous inhibitor of protein phosphatase 2A (CIP2A), also designated p90 autoantigen or KIAA1524, is a single-pass membrane protein that exhibits oncogenic activity. CIP2A is known to inhibit PP2A (protein phosphatase 2A) dephosphorylation of c-Myc, thereby stabilizing c-Myc (an oncogenic transcription factor) and promoting tumor formation and malignant cell growth. PP2A is a trimeric protein complex consisting of three subunits: a scaffold subunit, a catalytic subunit and a regulatory subunit. CIP2A specifically interacts with the catalytic subunit of PP2A to inhibit its activity. Inhibition of PP2A activity is a crucial step allowing for the progression of human cell transformation. Further supporting its role as an oncoprotein, CIP2A is known to be overexpressed in colon, gastric, and head and neck squamous cell carcinomas.
